Skip to content
Sign in

Company

Tenax Therapeutics, Inc.

Open structure map

Structure of Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc.

Company

4 connections
ConstraintsRegulation and exposure
OwnProducts and technology
Relationship began2026
Tenax Therapeutics, Inc.Company · 4 connections
Layer 1

OwnProducts and technology2

ConstraintsRegulation and exposure2

Place in the network

No. 10404 of 118934top 9%up 6943 places this week

3 direct links

In a group of 990 closely linked entities, around

New links this week

Weighted by public relations with evidence, recomputed daily.

Relations

Arrows show the direction of the relationship. Filter to focus on a business area.

  • Tenax Therapeutics, Inc.uses →levosimendan
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-06 10:21
      Tenax's prioritized product candidate is levosimendan, which the Company evaluated through, *inter alia*, its Phase 3 LEVEL study of oral levosimendan, or TNX-103, in pulmonary hypertension in heart failure with preserved ejection fraction ("PH-HRpEF").
      View source
    • CompanyPR Newswire news releases2026-11-06 10:21
      Tenax conducted and completed its Phase 2 HELP study of levosimendan
      View source
    • CompanyPR Newswire news releases2026-10-30 21:06
      Its prioritized product candidate is levosimendan, which it evaluated in the Phase 3 LEVEL study as TNX-103.
      View source
    • CompanyPR Newswire news releases2026-10-30 21:06
      which it evaluated in the Phase 3 LEVEL study as TNX-103.
      View source
    • CompanyPR Newswire news releases2026-10-28 10:25
      Tenax's prioritized product candidate is levosimendan
      View source
  • Tenax Therapeutics, Inc.uses →TNX-103
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-10-28 10:25
      its Phase 3 LEVEL study of oral levosimendan, or TNX-103
      View source
  • Tenax Therapeutics, Inc.manufactures →TNX-103
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-09 22:25
      Tenax Therapeutics is a development-stage pharmaceutical company that develops novel cardiopulmonary therapies in the United States.
      View source
    • CompanyPR Newswire news releases2026-11-09 16:32
      Tenax revealed that its Phase 3 LEVEL trial of TNX-103 failed to meet its primary and secondary endpoints.
      View source
  • Tenax Therapeutics, Inc.located in →San Diego
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-09 22:25
      SAN DIEGO, Nov. 9, 2026 /PRNewswire/ --
      View source
  • Tenax Therapeutics, Inc.regulated by →Securities Exchange Act of 1934
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-09 22:25
      the *Tenax Therapeutics* class action lawsuit charges Tenax Therapeutics as well as certain of Tenax Therapeutics' top current and former executives with violations of the Securities Exchange Act of 1934.
      View source
  • Tenax Therapeutics, Inc.supplies →TNX-103
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-09 22:25
      Tenax Therapeutics announced that the U.S. Food and Drug Administration had cleared Tenax Therapeutics' Investigational New Drug Application for TNX-103 (levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction, and that accordi…
      View source
  • Tenax Therapeutics, Inc.produces →Cardiopulmonary therapies
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-16 22:49
      develops novel cardiopulmonary therapies
      View source
  • Tenax Therapeutics, Inc.part of →pharmaceutical industry
    Fact90%
    View evidence
    • CompanyPR Newswire news releases2026-11-16 22:49
      is a development-stage pharmaceutical company
      View source

Showing 1 to 8 of 9

Claims

Read the assertion alongside its sources. Expand a row to inspect the evidence.

FactEvidence 2

Tenax is a development-stage pharmaceutical company focused on novel cardiopulmonary therapies.

PR Newswire news releases · 2026-11-17 09:16

View evidence
  • CompanyPR Newswire news releases2026-11-17 09:16
    Tenax is a development-stage pharmaceutical company focused on novel cardiopulmonary therapies.
    View source
  • CompanyPR Newswire news releases2026-11-06 10:21
    Tenax is a Phase 3, development-stage pharmaceutical company that develops novel cardiopulmonary therapies.
    View source
FactEvidence 2
tickerTENX

Tenax Therapeutics, Inc. (NASDAQ: TENX) securities

PR Newswire news releases · 2026-11-17 09:16

View evidence
  • CompanyPR Newswire news releases2026-11-17 09:16
    Tenax Therapeutics, Inc. (NASDAQ: TENX) securities
    View source
  • CompanyPR Newswire news releases2026-11-02 03:30
    Tenax Therapeutics, Inc. (NASDAQ: TENX)
    View source
FactEvidence 1

is a development-stage pharmaceutical company

PR Newswire news releases · 2026-11-16 22:49

View evidence
  • CompanyPR Newswire news releases2026-11-16 22:49
    is a development-stage pharmaceutical company
    View source
FactEvidence 1

develops novel cardiopulmonary therapies

PR Newswire news releases · 2026-11-16 22:49

View evidence
  • CompanyPR Newswire news releases2026-11-16 22:49
    develops novel cardiopulmonary therapies
    View source
FactEvidence 1
closing price1.38 $ per share

to close at approximately $1.38 per share on August 10, 2026.

PR Newswire news releases · 2026-11-16 22:49

View evidence
  • CompanyPR Newswire news releases2026-11-16 22:49
    to close at approximately $1.38 per share on August 10, 2026.
    View source
FactEvidence 1
suppliesTNX-103

Tenax Therapeutics announced that the U.S. Food and Drug Administration had cleared Tenax Therapeutics' Investigational New Drug Application for TNX-103 (levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction, and that accordi…

PR Newswire news releases · 2026-11-09 22:25

View evidence
  • CompanyPR Newswire news releases2026-11-09 22:25
    Tenax Therapeutics announced that the U.S. Food and Drug Administration had cleared Tenax Therapeutics' Investigational New Drug Application for TNX-103 (levosimendan) for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction, and that accordi…
    View source

Showing 1 to 6 of 26

Market and valuation

Valuation data is available on Pro and Research.

Included in Pro

Suggest a page to watch

Know a page of this company that matters, such as pricing, a changelog, terms or careers? Suggest it. We read every suggestion; a page we add is watched for everyone, and we only count a change when two looks in a row agree.

Sign in to suggest a page

Not available: Company signals · Financials · Filings · Sites · Guidance